Related references
Note: Only part of the references are listed.Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
Nikolaus Marx et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors JACC State-of-the-Art Review
Thomas A. Zelniker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
Vikas S. Sridhar et al.
DIABETES OBESITY & METABOLISM (2020)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
Karen M. Hallow et al.
DIABETES OBESITY & METABOLISM (2018)
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Proposal of a Novel Mechanism of Action
Milton Packer et al.
JAMA CARDIOLOGY (2017)
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Hiddo J. L. Heerspink et al.
CIRCULATION (2016)
Share Paper
